Skip to main content
← All trials
Recurrent Lung Non-Small Cell CarcinomaGeneticsCancerLungs and breathingProcedureBiologicalDrugPhase 2

What this study is

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.

What's being tested

  • Biospecimen Collection

    Intervention · PROCEDURE

    Undergo blood and urine sample collection

  • Computed Tomography

    Intervention · PROCEDURE

    Undergo CT scan

  • Lymphoscintigraphy

    Intervention · PROCEDURE

    Undergo lymphoscintigraphy scan

  • Magnetic Resonance Imaging

    Intervention · PROCEDURE

    Undergo MRI

  • Ramucirumab

    Intervention · BIOLOGICAL

    Given IV

  • Tepotinib

    Intervention · DRUG

    Given PO

Study details

Official title
A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Sponsor
SWOG Cancer Research Network
Conditions
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Enrolling
56 people
Starts
2024-08-08
Est. completion
2028-05-31
Design
Open-label, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗